NCT00688597View on ClinicalTrials.gov

Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 8, 2008

Primary Completion Date

December 14, 2009

Study Completion Date

December 14, 2009

Conditions
Pompe Disease
Interventions
DRUG

Duvoglustat

Powder in a bottle for dissolution in water for oral administration

Trial Locations (1)

30033

Decatur

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY

NCT00688597 - Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease | Biotech Hunter | Biotech Hunter